MAU
ICPT

MRA Associates USA’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

MRA Associates USA’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-120
Closed -$9.55K – 172
2019
Q2 		$9.55K Buy
+120
New +$10.7K 0.04% 108

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MRA Associates USA's ICPT Position: Q3 2019 in Review

MRA Associates USA sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 120 shares — an estimated $9.55K sold.

MRA Associates USA first reported a position in ICPT in Q2 2019 and held it in 1 quarter. The position peaked at $9.55K in Q2 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

  • MRA Associates USA reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • MRA Associates USA sold 120 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $9.55K.
  • MRA Associates USA first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • MRA Associates USA's Intercept Pharmaceuticals, Inc. position peaked at $9.55K in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on MRA Associates USA's 13F filing for Q3 2019, filed 8 Nov 2019.